Targeting the insulin-like growth factor network in cancer therapy

During the last decades, changes in the insulin-like growth factor (IGF) signaling have been related to the pathogenesis of cancer. Therefore, IGFs became highly attractive therapeutic cancer targets. Several drugs including monoclonal antibodies (mAB), small molecule tyrosine kinase inhibitors (RTK...

Full description

Saved in:
Bibliographic Details
Published in:Cancer biology & therapy 2011-04, Vol.11 (8), p.701-707
Main Authors: Heidegger, Isabel, Pircher, Andreas, Klocker, Helmut, Massoner, Petra
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - metabolism
Antibodies, Monoclonal - therapeutic use
Binding
Biology
Bioscience
Calcium
Cancer
Cell
Clinical Trials as Topic
Cycle
Humans
Insulin-Like Growth Factor Binding Proteins - metabolism
Insulin-Like Growth Factor I - metabolism
Landes
Molecular Targeted Therapy
Neoplasms - drug therapy
Neoplasms - metabolism
Oligoribonucleotides, Antisense - genetics
Oligoribonucleotides, Antisense - metabolism
Organogenesis
Protein Binding - drug effects
Protein Kinase Inhibitors - therapeutic use
Proteins
Receptor Protein-Tyrosine Kinases - antagonists & inhibitors
Receptor, IGF Type 1 - antagonists & inhibitors
Receptor, IGF Type 1 - genetics
Signal Transduction - drug effects
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During the last decades, changes in the insulin-like growth factor (IGF) signaling have been related to the pathogenesis of cancer. Therefore, IGFs became highly attractive therapeutic cancer targets. Several drugs including monoclonal antibodies (mAB), small molecule tyrosine kinase inhibitors (RTKIs), anti-sense oligonucleotids (ASOs) and IGF-binding proteins (IGFBPs) targeting the IGF axis were developed. With over 60 ongoing clinical trials, the IGF1 receptor (IGF1R) is currently one of the most studied molecular targets in the field of oncology. In this review, we provide an overview on the IGF axis, its signaling pathways and its significance in neoplasia. We critically review the preclinical and clinical studies investigating the role of IGF1R as a cancer target and discuss preliminary results and possible limitations.
ISSN:1538-4047
1555-8576
DOI:10.4161/cbt.11.8.14689